The primary purpose of the Organic Synthesis Facility (OSF) is to produce the highest quality synthetic molecules for Fox Chase Cancer Center (FCCC) investigators. The OSF was used by 19 investigators with peer-reviewed funding in calendar year 2009. Over eighty-five percent (85.4%) of use was in support of peer-reviewed, funded investigators in calendar year 2009. Small organic molecules are used in many areas of research as specific reagents including those that are inhibitors of enzyme activity or protein binding. Some of these molecules have been used in the development of prodrugs against target proteins identified at FCCC. Analogues of natural substrates have been used to probe enzyme mechanism, to investigate protein function, or to lest specific hypotheses. The molecules synthesized by the Facility are not purchasable from chemical companies, and custom synthesis from commercial enterprises is either not available or prohibitively expensive. The demand for synthetic services and especially the demand for novel compound synthesis have increased significantly over this current funding period. In order to meet this need, the efficiency and productivity of the Facility have been increased with the addition of a seasoned Ph.D. chemist to the staff and by acquisition of a new LC-MS system. In addition to increasing efficiency, the LC-MS system provides the Facility with new capabilities and services. During the last grant period (calendar years 2006-2009), 79 different chemical syntheses were completed including 44 novel compounds for 17 investigators in four Research Programs. The compounds synthesized were very diverse in structure and included a series of tamoxifen analogues, drug-conjugated antibodies, p53 inhibitors, Paki inhibitors, and photosensitizers. The OSF provided analytical, purification and consulting services to 46 investigators from all five Research Programs and seven Shared Facilities during the current funding period. In the last four calendar years (2006-2009), the average number of requests for these analytical and purification services was 59 per month, compared to 34 in calendar years 2000-2004. The large user group of 46 investigators from all five Research Programs and seven Shared Facilities indicates that the materials produced and services provided by the Facility are necessary for the scientific objectives of a wide range of research projects being carried out throughout the Center.

Public Health Relevance

Macromolecular interactions are central to all biological processes, including those involved in the development of cancer. These interactions either directly involve small organic molecules or can be modified by them. Modern biological research therefore requires the availability of organic compounds.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
7P30CA006927-50
Application #
8475339
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
50
Fiscal Year
2013
Total Cost
$23,949
Indirect Cost
Name
Research Institute of Fox Chase Cancer Center
Department
Type
DUNS #
064367329
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Malik, R; Luong, T; Cao, X et al. (2018) Rigidity controls human desmoplastic matrix anisotropy to enable pancreatic cancer cell spread via extracellular signal-regulated kinase 2. Matrix Biol :
Giri, Veda N; Obeid, Elias; Hegarty, Sarah E et al. (2018) Understanding of multigene test results among males undergoing germline testing for inherited prostate cancer: Implications for genetic counseling. Prostate 78:879-888
Anari, Fern; O'Neill, John; Choi, Woonyoung et al. (2018) Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial. Eur Urol Oncol 1:54-60
Drilon, Alexander; Laetsch, Theodore W; Kummar, Shivaani et al. (2018) Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 378:731-739
Nacson, Joseph; Krais, John J; Bernhardy, Andrea J et al. (2018) BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance. Cell Rep 25:1384
Nikonova, Anna S; Deneka, Alexander Y; Kiseleva, Anna A et al. (2018) Ganetespib limits ciliation and cystogenesis in autosomal-dominant polycystic kidney disease (ADPKD). FASEB J 32:2735-2746
Singh, Tanu; Lee, Eric H; Hartman, Tiffiney R et al. (2018) Opposing Action of Hedgehog and Insulin Signaling Balances Proliferation and Autophagy to Determine Follicle Stem Cell Lifespan. Dev Cell 46:720-734.e6
Di Marcantonio, Daniela; Martinez, Esteban; Sidoli, Simone et al. (2018) Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia. Clin Cancer Res 24:608-618
Gabbasov, Rashid; Xiao, Fang; Howe, Caitlin G et al. (2018) NEDD9 promotes oncogenic signaling, a stem/mesenchymal gene signature, and aggressive ovarian cancer growth in mice. Oncogene 37:4854-4870
Nacson, Joseph; Krais, John J; Bernhardy, Andrea J et al. (2018) BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance. Cell Rep 24:3513-3527.e7

Showing the most recent 10 out of 1280 publications